Epigenetic reprogramming refers to the process of resetting epigenetic marks—DNA methylation patterns, histone modifications, and chromatin accessibility—to a more youthful state without necessarily converting cells to pluripotent stem cells. This approach has emerged as one of the most promising anti-aging and neurodegeneration therapeutic strategies, with several companies advancing programs toward clinical translation. [1]
Partial reprogramming using the Yamanaka factors (OCT4, SOX2, KLF4, c-MYC, or subsets thereof) can reverse epigenetic aging while avoiding the tumorogenic risks associated with full pluripotency. Research has demonstrated that cyclic or controlled expression of these factors can improve tissue function, reverse age-related transcriptomic changes, and promote regeneration in multiple organ systems including the brain. [2]
--- [3]
NewLimit is a biotechnology company founded in 2022 by Brian Armstrong (co-founder and CEO of Coinbase) and Blake Byers (genomics scientist formerly at Google). The company is focused on developing epigenetic reprogramming therapies to treat age-related diseases, with an initial focus on immune senescence and potential applications in neurodegeneration. [4]
| Attribute | Details | [5]
|-----------|---------|
| Founded | 2022 |
| Headquarters | South San Francisco, CA |
| Founders | Brian Armstrong, Blake Byers |
| CEO | Brian Armstrong |
| Funding | $400M+ Series B (December 2023) |
| Pipeline | T cell rejuvenation, liver regeneration, CNS programs (preclinical) |
NewLimit's approach combines:
NewLimit has developed:
The Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) are transcription factors that can reset somatic cells to pluripotency. However, partial reprogramming involves expressing these factors transiently or using subsets to achieve rejuvenation without full dedifferentiation.
Izpisua Belmonte group (2016) — First demonstration that cyclic expression of OSK could reverse epigenetic aging in mice without tumors 1
Horvath and colleagues (2023) — Epigenetic clock analysis shows partial reprogramming can reduce biological age by 30-50% in human cells 2
Lu et al. (2020) — In vivo partial reprogramming improved vision and nerve regeneration in mice 3
Chen et al. (2021) — Transient reprogramming reversed age-associated changes in human fibroblasts while maintaining cell identity 4
Gill et al. (2022) — Multi-omic rejuvenation of human cells by maturation phase transient reprogramming 5
| Factor Combination | Effect | Tumor Risk | Cell Identity |
|---|---|---|---|
| OSK only | Partial rejuvenation | Low | Retained |
| OSK + c-MYC | Enhanced proliferation | Moderate | Partially lost |
| Full OSKM | Full pluripotency | High | Completely lost |
| Novel cocktails | Optimized rejuvenation | Low-Moderate | Retained |
| Company | Focus | Key Differentiator |
|---|---|---|
| Altos Labs | Broad rejuvenation | Yamanaka + Rick Klausner, $3B+ funding |
| Calico (Alphabet) | Aging + longevity | Artificial intelligence platform |
| Retro Biosciences | Cellular reprogramming | $180M, cellular rejuvenation |
| Life Biosciences | Epigenetic reprogramming | Broad aging focus |
| Shift Bioscience | Controlled reprogramming | Numeric gene expression control |
Epigenetic reprogramming and senolytic approaches represent complementary strategies:
| Aspect | Epigenetic Reprogramming | Senolytics |
|---|---|---|
| Mechanism | Reverse epigenetic age | Clear senescent cells |
| Target | All cell types | Senescent cells only |
| Risk | Oncogenic (managed) | Off-target effects |
| Stage | Preclinical | Early clinical |
Ocampo et al. In Vivo Amelioration of Age-Associated Traits by Epigenetic Reprogramming (Cell, 2016). 2016. ↩︎
Browder et al. In vivo partial reprogramming alters age-associated molecular changes while protecting cellular identity (Cell Stem Cell, 2022). 2022. ↩︎
Lu et al. Reprogramming to Recover Youthful Epigenetic Information and Restore Vision (Nature, 2020). 2020. ↩︎
Chen et al. In vivo partial reprogramming alters age-associated molecular changes while protecting cellular identity (Nature Aging, 2021). 2021. ↩︎
Gill et al. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming (Nature, 2022). 2022. ↩︎